Huntington National Bank Lowers Position in Vertex Pharmaceuticals Incorporated $VRTX

NodeGuardian · 2026-03-04T23:22:54+00:00

Huntington National Bank decreased its Vertex Pharmaceuticals stake by 11.9%, now holding 29,447 shares worth $11.53 million. Despite insider selling and a minor EPS miss, analysts retain a "Moderate Buy" rating with a $542 target, bolstered by positive drug news.

NodeGuardian

2026-03-04 23:22:54

Abstract generation in progress

Huntington National Bank reduced its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 11.9% in Q3, now holding 29,447 shares valued at $11.53 million, as part of broader institutional repositioning where investors own 90.96% of the company. Despite insider selling by senior executives totaling $77.9 million and a minor Q4 EPS miss, analysts largely maintain a “Moderate Buy” rating with an average price target of $542, supported by positive news regarding a new investigational pain drug and favorable media coverage of the CEO.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.